• About us
• Contact

Advertisement

Organisation › Details

DNA Script (Group)

Founded in 2014 in Paris, DNA Script is the world’s leading company in manufacturing de novo synthetic nucleic acids using an enzymatic technology. The company aims at accelerating innovation in life sciences and technology through rapid, affordable, and high-quality DNA synthesis. DNA Script’s approach leverages nature’s billions of years of evolution in synthesizing DNA to enable genome scale synthesis. The Company’s technology has the potential to greatly accelerate the development of new therapeutics, sustainable chemicals production, improved crops as well as data storage. DNA Script recently announced the raise of a Series A financing of $13 million led by Illumina Ventures, with additional investments from M Ventures, the corporate venture arm of Merck KGaA, Darmstadt, Germany, plus existing investors Sofinnova Partners, Kurma Partners, and Idinvest Partners. *

 

	Start	2014-03-20 established
	Today	DNA Script SAS
	Industry	DNA synthesis
	Industry 2	enzyme technology
	Person	Ybert, Thomas (DNA Script 201709 CEO + Co-Founder)
	Person 2	Gariel, Sylvain (DNA Script 201709 COO + Co-Founder)
	Region	Paris
	Country	France
	Street	29 Rue du Faubourg Saint-Jacques
	City	75014 Paris
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2024-02-12

Advertisement

More documents for DNA Script (Group)

• [1] DNA Script. (5/10/22). "Press Release: DNA Script Appoints Chris Barbazette as Chief Commercial Officer". South San Francisco, CA....
• [2] DNA Script. (4/5/22). "Press Release: DNA Script Partners with Asia-Pacific Distributors as Part of Global Expansion to Meet Demand for Same-day Enzymatic DNA Synthesis". South San Francisco, CA & Paris....
• [3] DNA Script. (1/4/22). "Press Release: DNA Script Closes $200 Million Series C Financing with Completion of Second Tranche". South San Francisco, CA & Paris....
• [4] DNA Script. (10/26/21). "Press Release: DNA Script Raises $165M in Oversubscribed Series C Financing to Accelerate Commercialization of Enzymatic DNA Printing Platform". South San Francisco, CA & Paris....
• [5] DNA Script. (6/15/21). "Press Release: DNA Script Announces the Commercial Launch of the Syntax System, the First Benchtop DNA Printer Powered by Enzymatic Synthesis, to Accelerate Molecular Biology and Genomics Workflows". South San Francisco, CA & Pari...
• [6] DNA Script. (4/27/21). "Press Release: DNA Script Partners with Moderna to Develop On-Demand Vaccines and Therapeutics for DARPA". Paris & Cambridge, MA....
• [7] DNA Script. (3/23/21). "Press Release: DNA Script Names Philippe Lyko as Chief Financial Officer". San Francisco, CA & Paris....
• [8] DNA Script. (7/29/20). "Press Release: DNA Script Expands Series B to $89M". Paris & South San Francisco, CA....
• [9] DNA Script. (1/15/20). "Press Release: IARPA Funds Team Involving DNA Script, the Broad Institute, and Harvard University for DNA Data Storage Research and Development". South San Francisco, CA....
• [10] DNA Script. (11/5/19). "Press Release: DNA Script to Open U.S. Office in South San Francisco to Support Commercialization of the Company's Industry-Leading Enzymatic Synthesis Technology". Paris....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.